Drugs / Indiplon
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00525941 | Sep 2007 → Jan 2008 | insomnia | Neurocrine Biosciences | Withdrawn | No outcome recorded |
| Phase 3 | NCT00232167 | Nov 2005 → Apr 2006 | insomnia, major depressive disorder | Neurocrine Biosciences | Terminated | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Indiplon | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00232167 ↗ |
| Known as | Calenthys | ChEMBL registry synonym — accepted as the source's own label CHEMBL262075 ↗ |
| Known as | CL-285489 | ChEMBL registry synonym — accepted as the source's own label CHEMBL262075 ↗ |
| Known as | Indiplone | ChEMBL registry synonym — accepted as the source's own label CHEMBL262075 ↗ |
| Known as | NBI-34060 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00525941 ↗ |
| Action | Activate | “GABA receptor alpha-1 subunit positive allosteric modulator” CHEMBL262075 ↗ |
| Modality | Small molecule | — CHEMBL262075 ↗ |
| Target | GABRA1 | “GABA receptor alpha-1 subunit positive allosteric modulator” CHEMBL262075 ↗ |